

## Kyowa Kirin announce changes in leadership positions

09 November 2022 | News

**Abdul Mullick appointed to global role reporting to Masashi Miyamoto, President and CEO of Kyowa Kirin**



Kyowa Kirin, a Japan-based Global Specialty Pharmaceutical company, has announced the appointment of Abdul Mullick, President, Kyowa Kirin International (KKI), to a new role in the global organisation, as Vice Chief International Business Officer, reporting to the Global President. Jeremy Morgan, SVP, Head of the International Rare Disease business, has been appointed President of Kyowa Kirin International.

In his new role, Abdul Mullick will work in collaboration with Toshifumi Mikayama, Executive Vice President, overseeing the North America (NA), Asia Pacific (APAC) and International/EMEA regions' business operations and the company's ongoing transformation to achieve the vision of becoming a Japan-based Global Specialty Pharmaceutical company.

During his 41?2 years as President of the International region, Mullick led the transformation of KKI, including establishing the company culture, building the rare disease and established medicines businesses, and ensuring a strong overall presence and impact in the market and for the patients served by the company's medicines.

In his new role, Mullick will focus on achieving the company vision and One Kyowa Kirin approach across all regions outside Japan for the global organisation.

Jeremy Morgan will serve as President of KKI following Abdul Mullick's move to the global organisation.

Both appointments take effect 1 January 2023. Mullick will relocate to the company headquarters in Tokyo, Japan. Morgan remains based in the international region headquarters in Marlow, UK.